Paper 28 - A PHASE 4, MULTICENTER, GLOBAL CLINICAL TRIAL TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB

Co-Author(s)

• JD

  Jayesh Desai, MBBS FRACP

  Peter MacCallum Cancer Centre
  Melbourne, Victoria, Australia
• 

  Andrew J. Wagner, MD, PhD

  Associate Professor of Medicine
  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States
• IC

  Irene Carrasco Garcia, MD

  Medical Oncologist
  Virgen del Rocio University Hospital
  Seville, Andalucia, Spain
• MC

  Marilena Cesari, MD

  Rizzoli Orthopedic Institute
  Bologna, Emilia-Romagna, Italy
• MG

  Michael Gordon, MD

  HonorHealth Research Institute
  Scottsdale, Arizona, United States
• 

  Chia-Chi Lin, MD, PhD

  Professor
  National Taiwan University Hospital
  Taipei, Taipei, Taiwan (Republic of China)
• ZP

  Zsuzsanna Papai, MD

  Semmelweis University
  Budapest, Budapest, Hungary
• CR

  Christopher W. Ryan, MD

  OHSU Knight Cancer Institute, South Waterfront
  Portland, Oregon, United States
• WT

  William D. Tap, MD

  Chief, Sarcoma Medical Oncology
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• 

  Jonathan Trent, MD, PhD

  Professor of Medicine
  Sylvester Comprehensive Cancer Center, University of Miami
  Miami, Florida, United States
• 

  Hans Gelderblom, MD, PhD (he/him/his)

  Medical Oncologist
  Leiden University Medical Center
  Leiden, Zuid-Holland, Netherlands
• 

  Peter Grimison, MD, PhD

  Senior Staff Specialist in Medical Oncology
  Chris O'Brien Lifehouse
  SYDNEY, New South Wales, Australia
• AL

  Antonio López Pousa, MD

  Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  Barcelona, Catalonia, Spain
• 

  Brian Andrew Van Tine, MD, PhD (he/him/his)

  Professor of Medicine
  Washington University School of Medicine
  St. Louis, Missouri, United States
• 

  Maria Rubinacci, MS, MBE (she/her/hers)

  Director, Clinical Operations GOMA
  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• KT

  Kristen Tecson, PhD

  Manager, Biostatistics
  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• MW

  Margaret Wooddell, PhD, MBA

  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States

Author(s)

• 

  Silvia Stacchiotti, MD (she/her/hers)

  Consultant
  Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  Milano, Lombardia, Italy

  Slides